Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Cetuximab
Other

Cetuximab

Tracked across 1 events · 8 articles · First seen May 21, 2026 · Last active Jun 01, 2026

Sentiment
0
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 0
Tech
Fulgent FID-007 Phase 2 Results
Impact: Cetuximab is a drug used in combination with FID-007 in the Phase 2 study, demonstrating synergistic effects in treating R/M HNSCC.
May 21, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Cetuximab live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.